Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Monk

Showing results (331-340 of 738) with videos related to

Pageof 74
Sort By:
JCO Precision Oncology|January 14, 2026
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian CancerRobert L Coleman, Rodney Rocconi, Bradley J Monk, et al.
Gynecologic Oncology|May 7, 2011
Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer studyThomas J Herzog, Jan B Vermorken, Eric Pujade-Lauraine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected]Edward L Nelson, Lari B Wenzel, Kathryn Osann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2015
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 studyB J Monk, P Ghatage, T Parekh, et al.
Future Oncology (London, England)|August 5, 2024
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapyJohn Nemunaitis, Laura Stanbery, Adam Walter, et al.
Gynecologic Oncology Reports|February 16, 2024
Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance settingBobbie J Rimel, Dana M Chase, Jessica Perhanidis, et al.
Gynecologic Oncology|September 28, 2010
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancerErnest S Han, Robert A Burger, Kathleen M Darcy, et al.
Gynecologic Oncology|July 29, 2015
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG studyJames S Ferriss, James J Java, Michael A Bookman, et al.
Gynecologic Oncology|July 20, 2024
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012Mitchell R Kamrava, Antonio Gonzalez-Martin, Bhavana Pothuri, et al.
Gynecologic Oncology|February 22, 2005
Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trialBradley J Monk, Jianmin Wang, Samuel Im, et al.
Pageof 74

Showing results (331-340 of 738) with videos related to

Sort By:
Pageof 74
JCO Precision Oncology|January 14, 2026
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian CancerRobert L Coleman, Rodney Rocconi, Bradley J Monk, et al.
Gynecologic Oncology|May 7, 2011
Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer studyThomas J Herzog, Jan B Vermorken, Eric Pujade-Lauraine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected]Edward L Nelson, Lari B Wenzel, Kathryn Osann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2015
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 studyB J Monk, P Ghatage, T Parekh, et al.
Future Oncology (London, England)|August 5, 2024
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapyJohn Nemunaitis, Laura Stanbery, Adam Walter, et al.
Gynecologic Oncology Reports|February 16, 2024
Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance settingBobbie J Rimel, Dana M Chase, Jessica Perhanidis, et al.
Gynecologic Oncology|September 28, 2010
Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancerErnest S Han, Robert A Burger, Kathleen M Darcy, et al.
Gynecologic Oncology|July 29, 2015
Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG studyJames S Ferriss, James J Java, Michael A Bookman, et al.
Gynecologic Oncology|July 20, 2024
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012Mitchell R Kamrava, Antonio Gonzalez-Martin, Bhavana Pothuri, et al.
Gynecologic Oncology|February 22, 2005
Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trialBradley J Monk, Jianmin Wang, Samuel Im, et al.
Pageof 74